Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease

被引：0
|
作者：
Tang, Mengyao [1 ,2 ]
Morieri, Mario Luca [3 ]
Kalim, Sahir [1 ,2 ]
Doria, Alessandro [2 ,4 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] Univ Padua, Dept Med, Padua, Italy
[4] Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年
关键词：
diabetic kidney disease;
D O I：
10.1681/ASN.0000000620
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
    Mone, Pasquale
    Ciccarelli, Michele
    Jankauskas, Stanislovas S.
    Guerra, Germano
    Vecchione, Carmine
    Visco, Valeria
    Santulli, Gaetano
    LANCET HEALTHY LONGEVITY, 2024, 5 (09):
  • [42] Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists in PTDM Treatment in Kidney Transplant Recipients: Synergistic Effect With Added Value in Terms of Nephroprotection
    Juric, Ivana
    Puljiz, Danijela Zjacic
    Jelakovic, Bojan
    Basic-Jukic, Nikolina
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (06) : 1264 - 1265
  • [43] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [44] Effect of an SGLT2 Inhibitor in Japanese Type 2 Diabetic Patients Receiving GLP-1 Receptor Agonists
    Onishi, Tetsuro
    Taniguchi, Yukiko
    Mori, Yutaka
    DIABETES, 2017, 66 : A324 - A324
  • [45] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [46] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [47] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [48] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [49] Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
    Honghong Zou
    Baoqin Zhou
    Gaosi Xu
    Cardiovascular Diabetology, 17
  • [50] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
12345